Arrowhead Pharmaceuticals Inc. (ARWR)


Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arrowhead Pharmaceuticals Inc. chart...

About the Company

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

$567M

Total Revenue

377

Employees

$3B

Market Capitalization

-11.92

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ARWR News

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

2d ago, source:

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for ...

Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value

22d ago, source: Yahoo Finance

Using the 2 Stage Free Cash Flow to Equity, Arrowhead Pharmaceuticals fair ... estimate of fair value How far off is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) from its intrinsic value?

Arrowhead Pharmaceuticals Inc ARWR

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arrowhead Pharmaceuticals files patent for RNAi agent for inhibiting SOD1 gene expression

5d ago, source: Pharmaceutical Technology

Discover how Arrowhead Pharmaceuticals' patented RNAi agents targeting the SOD1 gene offer hope for treating ALS and other neurodegenerative diseases. Learn about the innovative therapeutic benefits ...

Arrowhead Pharmaceutical Gains Over Initiation Of Phase 1/2a Study Of ARO-DM1

20d ago, source: Business Insider

(RTTNews) - Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) are climbing over 6 percent on Friday morning following the announcement of initiation of phase 1/2a study of ARO-DM1 for the treatment ...

These Numbers Prove Just How Vibrant The Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Stock Has Been

17d ago, source:

To see how Arrowhead Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: ARWR stock’s performance was 0.75% in the latest trading, and ...

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

2d ago, source: Stockhouse

New SHASTA-2 Phase 2 clinical data in patients with severe hypertriglyceridemia to be presented at ACC.24 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an ...

Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR)

3mon ago, source: Nasdaq

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...

Arrowhead Pharmaceuticals Inc.

13d ago, source: U.S. News & World Report

Picking the best bond ETF can be hard with so many options available. Here's what the experts suggest focusing on.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...